ID   NCI-H69/LX20
AC   CVCL_2139
SY   H69/LX20
DR   CLO; CLO_0008106
DR   cancercelllines; CVCL_2139
DR   ECACC; 96042332
DR   Wikidata; Q54908106
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1579 ! NCI-H69
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//